Clinical Trials Logo

Clinical Trial Summary

The aim of this study is to see whether the combination of 3 drugs (axitinib, avelumab and palbociclib) is safe and effective in slowing down the growth of advanced clear cell renal cell carcinoma (ccRCC) in patients that have not received any prior systemic treatment. The names of the study drug involved in this study are/is: - Axitinib - Avelumab - Palbociclib


Clinical Trial Description

This is a multi-center, single-arm, phase 2 study to evaluate the efficacy of the combination of axitinib, avelumab, and palbociclib in patients with untreated, advanced clear cell renal cell carcinoma (ccRCC). This research study involves an investigational drug combination (axitinib, avelumab and palbociclib) not approved by the FDA (USA Food and Drug Administration) for treatment of advanced clear cell renal cell carcinoma (ccRCC), though the combination of axitinib and avelumab has been approved for use in advanced clear cell renal cell carcinoma (ccRCC) treatment. Palbociclib is a CDK inhibitor, which targets growing cancer cells by blocking how a phosphate molecule is added to an important regulatory protein called retinoblastoma so preventing the formation of new cancer cells. Study procedures include screening for eligibility, study treatment, participant evaluations and safety follow visits in addition to general health status follow-up after study treatment. Participants will receive study treatment for as long as they do not have serious side effects and their disease does not get worse, and will be followed for as long as they remain on the study. It is expected that about 25 people will take part in this research study. Pfizer is supporting this research study by providing the study drugs (axitinib, avelumab and palbociclib). ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05176288
Study type Interventional
Source Dana-Farber Cancer Institute
Contact
Status Withdrawn
Phase Phase 2
Start date May 31, 2024
Completion date August 31, 2027

See also
  Status Clinical Trial Phase
Not yet recruiting NCT05440045 - A Clinical Study of 6MW3211 in Patients With Renal Cancer Phase 2
Active, not recruiting NCT05122546 - CBM588 in Combination With Nivolumab and Cabozantinib for the Treatment of Advanced or Metastatic Kidney Cancer Phase 1
Active, not recruiting NCT04904302 - Sitravatinib and Nivolumab for the Treatment of Metastatic or Advanced Clear Cell Renal Cell Cancer Phase 2
Recruiting NCT06399419 - CBM588 Capsules in Combination With Nivolumab and Ipilimumab for the Treatment of Advanced Stage Kidney Cancer Phase 1
Recruiting NCT05012371 - Lenvatinib With Everolimus Versus Cabozantinib for Second-Line or Third-Line Treatment of Metastatic Renal Cell Cancer Phase 2
Recruiting NCT05361720 - Genetic Testing to Select Therapy for the Treatment of Advanced or Metastatic Kidney Cancer, OPTIC RCC Study Phase 2
Terminated NCT03260504 - Aldesleukin and Pembrolizumab in Treating Patients With Advanced or Metastatic Kidney Cancer Phase 1